Filing Details

Accession Number:
0001209191-11-057332
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-11-21 14:15:24
Reporting Period:
2011-11-21
Filing Date:
2011-11-21
Accepted Time:
2011-11-21 14:15:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1466301 Clovis Oncology Inc. CLVS Pharmaceutical Preparations (2834) 900475355
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1051411 T Erle Mast C/O Clovis Oncology, Inc.
2525 28Th Street, Suite 100
Boulder CO 80301
Executive Vp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-21 2,378 $0.00 203,528 No 4 C Direct
Common Stock Acquisiton 2011-11-21 2,378 $0.00 205,906 No 4 C Direct
Common Stock Acquisiton 2011-11-21 5,147 $0.00 211,053 No 4 C Direct
Common Stock Acquisiton 2011-11-21 2,207 $0.00 213,260 No 4 C Direct
Common Stock Acquisiton 2011-11-21 5,323 $13.00 218,583 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Convertible Preferred Stock Disposition 2011-11-21 6,897 $0.00 2,378 $0.00
Common Stock Series A-2 Convertible Preferred Stock Disposition 2011-11-21 6,897 $0.00 2,378 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2011-11-21 14,928 $0.00 5,147 $0.00
Common Stock Convertible Promissory Notes Disposition 2011-11-21 0 $0.00 2,207 $13.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The reported securities were convertible at any time, in whole or in part, at the option of the reporting person, had no expiration date, and automatically converted into shares of Common Stock on November 21, 2011, the closing of the Issuer's initial public offering, on a 2.9 for 1 basis.
  2. The outstanding $28,000 principal amount of these 5% convertible promissory notes due May 25, 2012 and all accrued and unpaid interest thereon from and after May 25, 2011 automatically converted into shares of Common Stock on November 21, 2011, the closing of the Issuer's initial public offering, at a conversion price of $13.00, the per share price to the public of the Common Stock sold in the Issuer's initial public offering.